Edition:
United Kingdom

Beigene Ltd (6160.HK)

6160.HK on Hong Kong Stock

71.10HKD
17 Jun 2019
Change (% chg)

HK$-4.25 (-5.64%)
Prev Close
HK$75.35
Open
HK$72.00
Day's High
HK$72.00
Day's Low
HK$71.05
Volume
44,700
Avg. Vol
43,792
52-wk High
HK$108.20
52-wk Low
HK$61.05

About

BeiGene, Ltd. is principally engaged in biopharmaceutical business. The Company is mainly engaged in the research and development, production and sales of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company's main products include Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) and... (more)

Overall

Beta: 1.04
Market Cap(Mil.): $7,484.62
Shares Outstanding(Mil.): 59.81
Dividend: --
Yield (%): --

Financials

  6160.HK Industry Sector
P/E (TTM): -- 103.12 37.45
EPS (TTM): -12.75 -- --
ROI: -42.36 7.69 12.16
ROE: -49.80 8.19 16.93

Earnings vs. Estimates